Results 241 to 250 of about 219,700 (321)

The Structure of Informal Learning in the Workplace—An Experience Sampling Approach

open access: yesHuman Resource Development Quarterly, EarlyView.
ABSTRACT This paper complements retrospective approaches to researching informal learning in the workplace with experience sampling. Since (conscious) informal learning is becoming increasingly important for successfully keeping pace with rapid changes in working environments, a clear understanding of the construct and its precise measurement are ...
Katja Häußermann, Tina Seufert
wiley   +1 more source

Longitudinal changes in health‐related quality of life after a breast cancer diagnosis in sub‐Saharan Africa: Evidence from the prospective ABC‐DO cohort

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Breast cancer is now the most common malignancy among women in sub‐Saharan Africa (SSA). Its impact on survivors’ quality of life and Global Health Status (GHS), however, remains inadequately studied in this setting. Here, using data from the African Breast Cancer‐Disparities in Outcomes (ABC‐DO) study, the authors examined GHS over time in
Shamsudeen Mohammed   +10 more
wiley   +1 more source

Long‐term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Tamoxifen is a cornerstone of endocrine therapy for estrogen receptor (ER)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Its long‐term benefits, however, may vary by progesterone receptor (PR) status. Here, using data from the Stockholm tamoxifen trials, the authors evaluated whether PR expression predicts
Anna E. Nordenskjöld   +8 more
wiley   +1 more source

Brixia score on initial chest X-ray as a predictor of outcome in COVID-19 and H1N1 acute chest infections: A retrospective study. [PDF]

open access: yesMedicine (Baltimore)
Khasawneh R   +6 more
europepmc   +1 more source

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR‐positive/HER2‐negative metastatic breast cancer: Real‐world data from the OPAL registry

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Balancing efficacy and tolerability is challenging in oncology, as standard dosing often prioritizes maximum tolerated doses over other patient needs. Here, the authors developed a predictive index to identify patients with increased probability of dose reduction in metastatic breast cancer and compared the real‐world effectiveness of ...
Patrick Marschner   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy